Aptamer Group Ltd Revenue and Competitors
Estimated Revenue & Valuation
- Aptamer Group Ltd's estimated annual revenue is currently $8.1M per year.
- Aptamer Group Ltd's estimated revenue per employee is $155,000
Employee Data
- Aptamer Group Ltd has 52 Employees.
- Aptamer Group Ltd grew their employee count by -15% last year.
Aptamer Group Ltd's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Director & CTO | Reveal Email/Phone |
3 | Automation and Technical Support Director | Reveal Email/Phone |
4 | Operations Project Manager | Reveal Email/Phone |
5 | Senior Cell Culture Scientist | Reveal Email/Phone |
6 | Senior Selection Scientist | Reveal Email/Phone |
7 | Senior Selection Scientist | Reveal Email/Phone |
8 | Senior Selection Scientist | Reveal Email/Phone |
9 | Business Development Associate Director | Reveal Email/Phone |
10 | Production Scientist | Reveal Email/Phone |
Aptamer Group Ltd Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is Aptamer Group Ltd?
Aptamer Group brings together various aptamer technology driven companies to provide a range of services to the life sciences industry. Over the coming decades aptamer technology will have a profound effect on the life science market helping provide more cost-effective solutions to end users. We aim to address market needs through our group which has companies specialising in: the provision of high quality R&D consumables and high throughput aptamer screening services through Aptasol, biomarker discovery and validation tools (Aptasort), diagnostics devices / reagents (Aptadx) and therapeutic lead compounds (Aptarx). Aptamers are nucleic acid molecules made from DNA or RNA. Aptamers bind to other molecules with a higher degree of specificity and sensitivity than antibodies. Aptamers also have few of the drawbacks associated with antibodies, making them suitable replacements in many applications. The aptamers we develop are used in a variety of areas of life sciences research ranging from R&D consumables; such as, fluorescence microscopy &, flow cytometry probes through to purification (immunoprecipitation-like) reagents. We develop aptamers for use in clinical and non-clinical diagnostics and as candidate molecules for targeted therapeutics. We have also developed a first in-kind biomarker discovery process, which is set to breathe new life into the proteomics market. Our aptamers are currently being used in a variety of scenarios where antibodies have failed and are being expertly combined with microfluidics, electrochemical sensors and various nanotechnologies. The manufacturing costs and development times for monoclonal antibodies are several times higher and several times longer than the corresponding aptamer-based solution. Low manufacturing costs and speed of delivery means aptamers can be used at some point along the drug discovery process to facilitate the development of diagnostics and treatments. Get our newsletter: https://aptamergroup.com/newsletter
keywords:N/AN/A
Total Funding
52
Number of Employees
$8.1M
Revenue (est)
-15%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Aptamer Group Ltd News
... had signed an agreement with Aptamer Group, a leading provider of ... Suda Limited, Vectura Group PLC, Taiwan Liposome Company, Ltd.,...
Interim results: Aptamer Group PLC (AIM:APTA), ... Provident Financial (LSE:PFG) Group PLC, Reach plc, RTW Venture Fund Ltd (LSE:RTWG) , S4...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $13.6M | 52 | -13% | N/A |
#2 | $10.3M | 52 | 2% | N/A |
#3 | $13.6M | 52 | 6% | N/A |
#4 | $12.6M | 52 | 6% | N/A |
#5 | $12.9M | 53 | -2% | N/A |